Assessing the progression of mild cognitive impairment to Alzheimer's disease: Current trends and future directions

Larry G. Brooks, David A. Loewenstein

Research output: Contribution to journalReview article

54 Scopus citations

Abstract

With the advent of advances in biomarker detection and neuropsychological measurement, prospects have improved for identifying and tracking the progression of Alzheimer's disease (AD) from its earliest stages through dementia. While new diagnostic techniques have exciting implications for initiating treatment earlier in the disease process, much work remains to be done to optimize the contributions of the expanding range of tools at the disposal of researchers and clinicians. The present paper examines recent work in cerebrospinal fluid biomarkers, magnetic resonance imaging, positron emission tomography, neuropsychological measures, and functional assessment. The strengths and weaknesses of current methodologies are explored and discussed. It is concluded that AD from its mild cognitive impairment state through dementia represents a continuous process, and that progression over time can best be accomplished by interval-level variables. Biomarkers that are most sensitive to early AD may not be the most optimal for monitoring longitudinal change, and it is likely that multivariate models incorporating cognitive measures, functional variables and biomarker data will be the most fruitful avenues for future research.

Original languageEnglish (US)
Article number28
JournalAlzheimer's Research and Therapy
Volume2
Issue number5
DOIs
StatePublished - 2010

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Fingerprint Dive into the research topics of 'Assessing the progression of mild cognitive impairment to Alzheimer's disease: Current trends and future directions'. Together they form a unique fingerprint.

  • Cite this